Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on September 05, 2017, 10:19:42 am
-
In a recent pair of trials, eight weeks of the triple-drug combination of Merck’s grazoprevir, ruzasvir and uprifosbuvir cured high rates of hepatitis C virus (HCV) in a diverse population of participants, including those with cirrhosis. This opens the door for more advanced research of the fixed-dose combination tablet of the three direct-acting antivirals.
The regimen includes the NS3/4A protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir and the NS5B polymerase inhibitor uprifosbuvir. Grazoprevir is already approved as a component of Merck’s Zepatier (grazoprevir/elbasvir), while ruzasvir and uprifosbuvir are experimental.
Read more...
https://www.hepmag.com/article/mercks-tripledrug-8week-hepatitis-c-regimen-shows-promise